F8 IL10

Drug Profile

F8 IL10

Alternative Names: Dekavil; F8-IL10; PF 06687234

Latest Information Update: 29 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Philogen
  • Developer Pfizer; Philogen
  • Class Antirheumatics; Cytokines; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Interleukin-10 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis; Ulcerative colitis
  • Phase I Inflammation

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Rheumatoid-arthritis in Italy (IV)
  • 31 Oct 2017 Phase-II clinical trials in Ulcerative colitis (Adjunctive treatment) in USA (SC) (NCT03269695)
  • 05 Sep 2017 Pfizer plans a phase II trial for Ulcerative colitis (Adjunctive treatment) in USA (SC) (NCT03269695)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top